Cholinesterase Inhibitors and Memantine Are the Two Types of Alzheimer's Drugs Approved By FDA

Alzheimer’s disease is a progressive neurodegenerative disorder that causes the death of neurons in the brain. The symptoms of Alzheimer’s disease can be devastating for a patient and their family, but there are ways to ease their suffering. Medications for Alzheimer’s are available to help slow the progress of the disease. There are also supplements that can help patients with the symptoms of Alzheimer’s.

While it can be difficult to recognize the symptoms of Alzheimer's Drugs, medications are available to help treat the symptoms and improve the patient's quality of life. The U.S. FDA approved several Alzheimer’s drugs to treat the earliest stages of the disease. These drugs can help people with the earliest symptoms of the disease, including forgetfulness. In addition, these drugs can be used for other stages of the disease, such as mild to moderate Alzheimer's. The specific drugs prescribed for Alzheimer’s depend on the symptoms and severity of the patient's disease.

The life expectancy of people with Alzheimer’s disease decreases. Those diagnosed with Alzheimer's disease typically live for seven to 10 years less. In later stages, the person has no ability to communicate and may spend much of their time in bed. In addition, there is no cure for Alzheimer's, and there is no cure. People suffering from Alzheimer’s disease can witness poor sleep quality, thereby elevating damage to cognitive health.

Cholinesterase inhibitors and memantine are the two types of Alzheimer's drugs approved by the U.S. Food and Drug Administration for the treatment of cognitive symptoms in Alzheimer’s disease. The cholinesterase inhibitors most commonly prescribed are Donepezil and Rivastigmine. Donepezil is used to treat confusion (dementia) related to Alzheimer's disease. Rivastigmine increases the levels of a brain chemical called acetylcholine which allows the nerve cells to communicate.